Equities

Assembly Biosciences Inc

Assembly Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.15
  • Today's Change0.34 / 2.65%
  • Shares traded4.56k
  • 1 Year change+9.58%
  • Beta0.5874
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.

  • Revenue in USD (TTM)7.16m
  • Net income in USD-61.23m
  • Incorporated2005
  • Employees65.00
  • Location
    Assembly Biosciences IncTwo Tower Place, 7Th FloorSOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (212) 554-4388
  • Fax+1 (646) 706-5101
  • Websitehttps://www.assemblybio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rallybio Corp0.00-74.56m69.20m43.00--0.652-----1.84-1.840.002.810.00----0.00-50.37---54.02--------------0.00-------11.87------
Regencell Bioscience Holdings Ltd0.00-7.45m69.36m12.00--4.06-----0.5863-0.58630.001.310.00----0.00-82.73---113.11--------------0.00------21.15------
Landos Biopharma Inc0.00-21.94m69.50m19.00--2.18-----3.49-3.490.0010.200.00----0.00-52.67-59.84-61.86-72.15-------795.80---516.520.00------44.15------
Champions Oncology Inc49.22m-9.73m69.74m230.00------1.42-0.7183-0.71833.64-0.15141.56--6.17214,017.40-30.91-5.40-96.45-11.8840.0947.96-19.76-3.09--------9.6921.63-1,073.54--18.50--
Yubo International Biotech Ltd604.68k-1.20m70.69m18.00------116.91-0.01-0.010.005-0.01540.30120.69129.1933,593.33-59.52------69.32---197.64--0.1504-3,143.97----479.86--0.8224------
vTv Therapeutics Inc0.00-20.25m71.13m16.00---------9.79-9.790.00-9.270.00----0.00-117.34-111.84-1,613.30---------680.94---------100.00---5.67------
Elutia Inc24.75m-41.25m71.35m54.00------2.88-2.20-2.081.35-1.660.44081.974.90458,240.80-73.48-42.93-309.94-79.3444.6743.32-166.70-64.160.6367-3.54-----49.69-8.71-25.39--12.74--
Celularity Inc14.79m-181.41m71.67m225.00--2.11--4.85-10.51-10.510.83761.560.04982.292.0365,724.45-61.05---82.37--21.19---1,226.72--0.136618.400.5365---15.75--114.18------
Assembly Biosciences Inc7.16m-61.23m72.10m65.00--1.75--10.07-14.02-14.021.637.500.06--14.51110,200.00-51.32-39.69-66.88-44.03-----854.78-409.24----0.00-----13.5134.23---5.59--
Precision BioSciences Inc48.73m-42.53m72.76m109.00--2.32--1.49-10.96-15.8612.684.530.2449--60.12447,036.70-21.37-35.35-29.50-44.22-----87.28-147.50----0.543--94.1534.9641.67---32.01--
VolitionRX Ltd775.30k-35.32m73.11m110.00------94.31-0.504-0.5040.0109-0.09530.0335--4.927,048.18-154.29-111.92---196.20-----4,601.71-10,793.31---280.52----153.04---16.68--29.13--
Instil Bio Inc0.00-156.09m73.49m49.00--0.3254-----24.00-24.000.0034.720.00----0.00-38.65---40.84--------------0.265------30.06------
Benitec Biopharma Inc61.00k-21.81m74.66m18.00--1.50--1,223.89-10.90-10.900.03045.970.0037--1.013,388.89-131.16-83.43-174.32-98.77172.1396.86-35,754.10-468.04---5,423.000.00--2.74-53.84-7.44---56.51--
Sellas Life Sciences Group Inc0.00-37.34m74.84m16.00---------1.37-1.370.00-0.24820.00----0.00-274.94-111.48---184.29-------1,289.42---------100.00--9.59------
Athira Pharma Inc0.00-117.67m75.12m65.00--0.5747-----3.09-3.090.003.410.00----0.00-56.25-30.73-63.93-32.46------------0.00-------23.04------
Bakhu Holdings Corp0.00-1.92m75.33m2.00---------0.0064-0.00640.00-0.03250.00----0.00-281.75-4,391.82---------------8.39--------33.37------
Data as of May 03 2024. Currency figures normalised to Assembly Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

11.10%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023193.33k3.53%
Millennium Management LLCas of 31 Dec 2023120.84k2.20%
BlackRock Fund Advisorsas of 31 Dec 202373.60k1.34%
Anson Funds Management LPas of 31 Dec 202359.96k1.09%
Geode Capital Management LLCas of 31 Dec 202351.00k0.93%
Renaissance Technologies LLCas of 31 Dec 202335.88k0.65%
Federated MDTA LLCas of 31 Dec 202325.39k0.46%
Acuitas Investments LLCas of 31 Dec 202322.13k0.40%
Bridgeway Capital Management LLCas of 31 Dec 202314.50k0.26%
SSgA Funds Management, Inc.as of 31 Dec 202312.11k0.22%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.